Skip to content
Calculator

Women · Hub

Women, pregnancy and peptides: what the labels and studies say

Most peptide writing ignores the questions women actually ask: is this safe if I get pregnant, can I breastfeed on it, does it stop my pill working, does it help PCOS, what changes after menopause? This section answers each from the drug's own label, the US National Library of Medicine's LactMed database and published studies, and says plainly where nobody has studied the question.

Last updated November 3, 2026 · Reviewed by Grey Peptides Editorial Board · ✓ Every claim sourced · No products sold, no seller named

Guide
Pregnancy and planning a pregnancy
Each label's section 8.1, the two-month semaglutide washout, and what research peptides lack.
Guide
Breastfeeding
LactMed's records and each label's section 8.2: what has been measured in milk, and what has not.
Guide
Contraception and GLP-1s
Why tirzepatide's label asks pill users to add a barrier method, and what the semaglutide study found.
Guide
PCOS
What the randomized trials and meta-analyses of GLP-1 drugs in PCOS found.
Guide
Menopause
The GLP-1 evidence in postmenopausal women, the bone-building peptides, and what is missing.
📋 Key takeaways

For an approved drug, the label is the authority. Section 8.1 covers pregnancy, 8.2 breastfeeding and 8.3 contraception and fertility. The GLP-1 labels say weight loss offers no benefit in pregnancy and may cause fetal harm, and tell patients using the drug for weight to stop when pregnancy is recognized.12

Semaglutide needs planning ahead. Its labels advise stopping at least two months before a planned pregnancy, because the drug takes that long to wash out.1

Tirzepatide and the pill. Zepbound's label says it may make oral contraceptives less effective and advises switching to a non-oral method, or adding a barrier method, for 4 weeks after starting and after each dose increase.2

Research peptides have no data at all. No label, no registry, no lactation study. For BPC-157, ipamorelin and CJC-1295 a PubMed search for pregnancy or breastfeeding returns nothing.7 That is an absence of evidence, not reassurance.

On this page

  1. Start here: which page you need
  2. What the labels say, in one table
  3. What the pregnancy studies show so far
  4. Breastfeeding in brief
  5. Research peptides: nothing to report, and why that matters
  6. Peptides approved for women's health
  7. Frequently asked questions
  8. Related on Grey Peptides
  9. Sources

Start here: which page you need

Pick the stage you are at. Each page quotes the labels word for word in a table, so you can check every sentence against DailyMed yourself, and links the encyclopedia entry for each drug.

  1. Pregnancy and planning a pregnancy. Each label's section 8.1, the two-month semaglutide washout, and what research peptides lack.
  2. Breastfeeding. LactMed's records and each label's section 8.2: what has been measured in milk, and what has not.
  3. Contraception and GLP-1s. Why tirzepatide's label asks pill users to add a barrier method, and what the semaglutide study found.
  4. PCOS. What the randomized trials and meta-analyses of GLP-1 drugs in PCOS found.
  5. Menopause. The GLP-1 evidence in postmenopausal women, the bone-building peptides, and what is missing.
  6. Peptides and women's health. The FDA-approved peptide drugs with women's-health indications.
  7. Peptides, GLP-1s, pregnancy and breastfeeding. The longer read, drug by drug.
  8. PCOS and peptides. Every PCOS trial we found, compound by compound.
  9. Peptides for menopause. The evidence table for menopausal women.
  10. GLP-1 drug interactions. Oral medicines, contraceptives, insulin and sulfonylureas.
  11. Starting a GLP-1. Prescribed, compounded or grey-market: the three routes.

What the labels say, in one table

Every US prescription label has a section 8, "Use in Specific Populations". For the GLP-1 drugs used for weight (semaglutide, tirzepatide and liraglutide), the message in 8.1 is the same: stop when pregnancy is recognized.1210 The table quotes the sentences that matter; the pregnancy page has the full set, including the bone, sexual-desire and growth-hormone-releasing peptides.

From the FDA label (quoted word for word from the current US label)

ProductWhat the label saysLabel section
Wegovy (semaglutide)“discontinue WEGOVY in patients at least 2 months before they plan to become pregnant to account for the long half-life of semaglutide”section 8.31
Ozempic injection (semaglutide)“Discontinue OZEMPIC in women at least 2 months before a planned pregnancy due to the long washout period for semaglutide”section 8.38
Rybelsus tablets (semaglutide)“Discontinue RYBELSUS or OZEMPIC tablets in women at least 2 months before a planned pregnancy due to the long washout period for semaglutide”section 8.39

Tirzepatide's labels carry no two-month line; the instruction they do carry is about contraception (see the contraception page).2 Whether a stop-before-conception gap is wise for tirzepatide is a question for the prescriber; we have found no label sentence that sets one.

What the pregnancy studies show so far

Labels lean on animal studies because almost no woman takes these drugs while pregnant on purpose. The human data come from accidental exposures in early pregnancy. The largest is a cohort from four Nordic countries, the US and Israel: compared with insulin, the adjusted relative risk of major congenital malformations after a GLP-1 drug around conception was 0.95 (95% CI 0.72 to 1.26), in 938 exposed infants of women with type 2 diabetes.3 A prospective study from six teratology information services found no excess of major birth defects in 168 first-trimester exposures, though its authors called the sample limited.4 A 2026 systematic review of 36 studies found early exposure was not consistently linked to malformations, stillbirth or neonatal death, and noted that data on use through the whole pregnancy remain limited.5

None of this makes the drugs approved for use in pregnancy. It means an accidental exposure in the first weeks has not so far shown a large signal in these studies (our reasoning, from the three studies above).

Breastfeeding in brief

LactMed, the National Library of Medicine's database on drugs and breastfeeding, reports that semaglutide was not detectable in the milk of mothers injecting it, and that tirzepatide is usually undetectable in breastmilk at the doses studied.6 The oral semaglutide tablets are different: they contain an absorption enhancer (SNAC) that is present in human milk, and the labels advise against breastfeeding on them.1 The breastfeeding page has the records drug by drug.

Research peptides: nothing to report, and why that matters

Compounds sold online as "research chemicals", such as BPC-157, ipamorelin or CJC-1295, have no label and therefore no section 8. On November 3, 2026 we searched PubMed for each name with pregnancy, lactation or breastfeeding: BPC-157, ipamorelin and CJC-1295 returned no records at all, and retatrutide's single record was a dermatology review, not a study.7 Retatrutide is still in trials; our retatrutide entry covers what they have reported.

No data means nobody knows. A product bought outside the regulated supply adds a second unknown: what is actually in the vial. Our grey-market guide covers what published tests of those products found.

Peptides approved for women's health

Several peptide drugs were approved for women specifically: bremelanotide for low sexual desire before menopause, oxytocin in labour, and teriparatide and abaloparatide for postmenopausal osteoporosis. Our women's health hub lists all of them from their labels. This section is its practical companion: what to do at each stage.

Frequently asked questions

I got pregnant while on semaglutide or tirzepatide. What now?

Tell your prescriber and obstetrician. The weight-loss labels say to stop when pregnancy is recognized. The studies of accidental early exposure so far have not found a large rise in major birth defects, but they are small and observational. Both drugs have pregnancy exposure registries; the numbers are in the labels.

Is it safe to use BPC-157 or another research peptide while trying to conceive?

Nobody knows. There is no label, no pregnancy study and no lactation study for any of them, and a PubMed search finds no human pregnancy data for BPC-157, ipamorelin or CJC-1295. Absence of data is not evidence of safety.

Where can I ask about a medicine in pregnancy?

Your obstetrician, midwife or pharmacist first. In the US, MotherToBaby answers questions about exposures in pregnancy and breastfeeding.

Pregnancy and planning a pregnancy Breastfeeding Contraception and GLP-1s PCOS Menopause Peptides and women's health Peptides, GLP-1s, pregnancy and breastfeeding PCOS and peptides Peptides for menopause GLP-1 drug interactions Starting a GLP-1

Sources

Labels are cited by their DailyMed set and version; LactMed by its revision date; studies by PMID, checked on PubMed. All read November 3, 2026.

  1. Wegovy (semaglutide) US prescribing information (Novo Nordisk; DailyMed set ee06186f, version 19, effective June 18, 2026), sections 7, 8 and 12. DailyMed
  2. Zepbound (tirzepatide) US prescribing information (Eli Lilly; DailyMed set 487cd7e7, version 40, effective August 28, 2026), sections 7, 8 and 12. DailyMed
  3. Cesta CE, Rotem R, Bateman BT, et al. Safety of GLP-1 Receptor Agonists and Other Second-Line Antidiabetics in Early Pregnancy. JAMA Intern Med 2024;184(2):144-152. PMID 38079178. Source
  4. Dao K, Shechtman S, Weber-Schoendorfer C, et al. Use of GLP1 receptor agonists in early pregnancy and reproductive safety: a multicentre, observational, prospective cohort study based on the databases of six Teratology Information Services. BMJ Open 2024;14(4):e083550. PMID 38663923. Source
  5. Ozbek L, et al. Safety of GLP-1 and Dual GLP-1/GIP Receptor Agonists in Preconception, Pregnancy, and Lactation: A Systematic Review of Maternal, Fetal, and Neonatal Outcomes. Diabetes Obes Metab 2026;28(6):4503-4528. PMID 41885132. Source
  6. Drugs and Lactation Database (LactMed), National Library of Medicine: Semaglutide (last revised August 15, 2026) and Tirzepatide (last revised August 15, 2026). Read November 3, 2026. Source
  7. PubMed searches run November 3, 2026 through NCBI E-utilities: 'BPC-157 AND (pregnan* OR lactation OR breastfeeding)' 0 records; 'ipamorelin AND (pregnan* OR lactation)' 0; 'CJC-1295 AND (pregnan* OR lactation)' 0; 'retatrutide AND (pregnan* OR lactation)' 1 (PMID 42562129, a dermatology review). Source
  8. Ozempic injection (semaglutide) US prescribing information (Novo Nordisk; DailyMed set adec4fd2, version 20, effective June 1, 2026), sections 7, 8 and 12. DailyMed
  9. Rybelsus tablets (semaglutide) US prescribing information (Novo Nordisk; DailyMed set 27f15fac, version 14, effective January 30, 2026), sections 7, 8 and 12. DailyMed
  10. Saxenda (liraglutide) US prescribing information (Novo Nordisk; DailyMed set 3946d389, version 22, effective February 25, 2026), sections 7, 8 and 12. DailyMed

This section reports what labels, LactMed and published studies say; it is not medical advice, and it does not replace the obstetrician, midwife, prescriber or pharmacist who knows your history. Grey Peptides sells nothing, links to no seller and rates none. If you are pregnant and have taken something you are unsure of, the MotherToBaby service (1-866-626-6847 in the US) answers questions about exposures in pregnancy and breastfeeding.